NCT00384631

Intravitreal Bevacizumab for Neovascular Glaucoma

Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: All
• Age: 10 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.

Conditions

• Neovascular
• Glaucoma

Interventions

Type	Name	Description
OTHER	subconjunctival normal saline	0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
DRUG	Avastin	intravitreal injection of avastin 2.5mg repeated twice at monthly intervals

Timeline

• Start date: 2006-04-01
• Completion: 2007-03-01
• First posted: 2006-10-06
• Last updated: 2008-02-15

Locations

1 site across 1 country: Iran